

Filed On Behalf Of:

C4 Therapeutics, Inc.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

C4 THERAPEUTICS, INC.

Petitioner

v.

FOGHORN THERAPEUTICS, INC.

Patent Owner

Case No. Not Yet Assigned

U.S. Patent No. 11,560,381

DECLARATION OF
CHRISTOPHER G. NASVESCHUK, Ph.D.
UNDER 37 C.F.R. §1.68 AND §42.53(a)

I, Christopher G. Nasveschuk, do hereby declare:


1. I make this declaration on behalf of Petitioner C4 Therapeutics, Inc. (C4T) in the matter of the Post Grant Review of U.S. Patent No. 11,560,381. Unless otherwise stated, the facts stated in this Declaration are based on my personal knowledge and experience. My Curriculum Vitae is provided as Attachment 1.
2. I received my B.S. degree in Chemistry from Middlebury College in 2001. I received a Ph.D. degree from Colorado State University in 2007. I was a Post-Doctoral Fellow under Andrew J. Phillips at the University of Colorado from 2007-2009. I then joined Constellation Pharmaceuticals, Inc. where the highest role I held was Research Scientist II. I left Constellation in 2014 to join the Broad Institute where the highest role I held was Senior Research Chemist II, where I stayed until joining C4T in 2016.
3. I have been employed by C4T since February 2016. I was initially appointed the Director of Degron Chemistry. In September 2016, I was named the Vice President of Chemical Sciences. In March 2021, I was promoted to Senior Vice President of Chemical Sciences.
4. From its time of inception to today, C4T has focused all of its research, discovery, and development efforts in the area of creating pharmaceutical

compounds that degrade proteins involved in disease states, and in particular, cancer.


5. At C4T, I built the Chemical Sciences team from the ground up across five functional areas: medicinal chemistry, process chemistry, DMPK (drug metabolism and pharmacokinetics), chemoinformatics, and computer-aided drug design. Among my responsibilities at C4T are overseeing C4T's discovery and development portfolios and managing our strategic partnership portfolios with Calico Life Sciences, Biogen, and Roche.
6. I am a listed co-inventor on WO 2021/178920 (Ex. 1010), titled "Compounds for Targeted Degradation of BRD9", along with Rhamy Zeid, Ning Yin, Katrina Jackson, Gesine Veits, Moses Moustakim and Jeremy Yap.
7. Our first provisional application in this family was filed March 5, 2020 (U.S.S.N. 62/985,774; Ex. 1012). Our second provisional was filed August 5, 2020 (U.S.S.N. 63/061,659; Ex. 1013) and our international PCT application was filed March 5, 2021 (PCT/US2021/021240; Ex. 1011). The PCT application published September 10, 2021 (WO 2021/178920; Ex. 1010; "'920 PCT Publication").

8. I have been asked to focus on the following compounds in the '920 PCT


Publication¹:




C4T Compound 70 Ex. 1010 at 679




C4T Compounds 172-176 Ex. 1010 at 704-705




C4T Compound 182 Ex. 1010 at 707



C4T Compound 184 Ex. 1010 at 707




C4T Compound 185 Ex. 1010 at 707




C4T Compound 187 Ex. 1010 at 708


¹ Citation is to Exhibit page number.




C4T Compound 188 Ex. 1010 at 708




C4T Compound 195 Ex. 1010 at 710




C4T Compound 198 Ex. 1010 at 711




C4T Compound 206 Ex. 1010 at 713




C4T Compound 225 Ex. 1010 at 717



C4T Compound 231 Ex. 1010 at 719



C4T Compound 251 Ex. 1010 at 724



C4T Compound 265 Ex. 1010 at 728

9. I declare that I have reviewed the synthetic examples of the '920 PCT Publication (Ex. 1010). I have identified the detailed synthesis of each of the above compounds in the '920 PCT Publication as indicated in Table 1 below.

Table 1


Compound	Cite² in Ex. 1010 ('920 PCT Publication)
70	410-411
172	528-531
173-176	540-547
182	533 (NMR, LCMS) synthesized following the synthesis of Cpd. 177
184	534 (NMR, LCMS) synthesized following the synthesis of Cpd. 177
185	534 (NMR, LCMS) synthesized following the synthesis of Cpd. 177
187	535 (NMR, LCMS) synthesized following the synthesis of Cpd. 177
188	536 (NMR, LCMS) synthesized following the synthesis of Cpd. 177
195	539 (NMR, LCMS) synthesized following the synthesis of Cpd. 177
198	556 (NMR, LCMS) synthesized following the synthesis of Cpd. 197
206	567-570
225	589 (NMR, LCMS) synthesized following the synthesis of Cpd. 218
231	596-600
251	620-624
265	649-650

² Citation is to Exhibit page number.

10. The syntheses of each of the compounds described above were carried out under my responsibility and direct supervision as Senior Vice President of Chemical Sciences. I confirm that these compounds were prepared and analyzed as described in the '920 PCT Publication at the relevant pages in Ex. 1010 indicated above and that the data is accurate.
11. I declare that I have reviewed Examples 1-14 and associated Figures 1-24 of the '920 PCT Publication (Ex. 1010).
12. Example 1 with data in Tables 1 and 2 of the '920 PCT Publication (Ex. 1010) describes a HiBIT Ligand Displacement Assay, which is a degradation assay that measures the concentration of the protein of interest via a decrease in luciferase luminescence that was done at C4T. The data in Tables 1 and 2 for the above-described compounds were generated at C4T. I was directly involved with the HiBIT compound assessments. I confirm that the reported HiBIT DC₅₀ binned data for the above-compounds is accurate.
13. Examples 2 and 3 of the '920 PCT Publication provide the pharmacology and chemical properties of Compounds 172 and 176, respectively. I was directly involved with these biochemical and *in vitro* pharmacology assessments. I confirm that the data in Examples 2 and 3 are accurate.
14. Examples 4-14 and their associated Figures 1-24 were carried out at or on behalf of C4T as part of the BRD9 project. I have personally confirmed that

the procedures, data and Figures are accurate by identifying and reviewing C4T reports held in the ordinary course of business that provide these procedures, data and Figures.

15. At C4T, we tested the ability of glutarimide to bind to cereblon using the following procedure.



Glutarimide

The ligand binding to CRBN-DDB1 was carried out using an established sensitive and quantitative *in vitro* fluorescence polarization (FP) based binding assay (*see* Nasir, M. S. and Jolley, M. E., "Fluorescence Polarization: An analytical tool for Immunoassay and Drug Discovery," *Combinatorial Chemistry & High Throughput Screening*, 1999, 2, 177-190). (Ex. 1022³). A semi-log serial dilution of the compound was prepared in DMSO starting with

³ I certify that Exhibit 1022 is a true and correct copy of Nasir, M. S. and Jolley, M. E., "Fluorescence Polarization: An analytical tool for Immunoassay and Drug Discovery," *Combinatorial Chemistry & High Throughput Screening* 2, 177-190 (1999).

3 M as a top concentration. The compound was then dispensed from serially diluted DMSO stock into black 384-well compatible fluorescence polarization plates using an Echo acoustic dispenser. Compound binding to CRBN-DDB1 was measured by displacement of the Alexa Fluor® labelled CRBN-DDB1 binding probe ($K_D = 2$ nM). A 20 μ L mixture containing 10 nM CRBN-DDB1 and 5 nM of fluorescent probe in 50 mM HEPES, pH 7.4, 200 mM NaCl, 1% DMSO, 0.1% bovine serum albumin, and 0.05% Pluronic F-127 acid was added to wells containing compound and incubated at room temperature for 90 minutes. Control wells with fully bound probe contained 150 nM of CRBN-DDB1 and were used for signal normalization. Matching control plates excluding CRBN-DDB1 were used to correct for background fluorescence. Plates were read on an Envision plate reader with appropriate FP filter sets. The corrected S (perpendicular) and P (parallel) values were used to calculate fluorescence polarization (FP) with the following equation:

$$FP = 1000 * (S - G * P) / (S + G * P)$$

The fractional amount of bound probe (FB) to CRBN-DDB1 as a function of compound concentration was fitted according to Wang; FEBS Letters 360,

(1995), 111-114 (Ex. 1023⁴) to obtain fits and binding constant (K_D) of tested compound.

16. Using the assay described in Paragraph 15, based on the average of at least 15 runs, we determined that glutarimide binds to cereblon with a K_D of 230 micromolar.

17. Based on my experience with heterobifunctional protein degradation compounds, I think it would be very difficult to administer enough heterobifunctional drug to a human to reach a concentration of 230 micromolar in the target human cells.

18. I carried out a theoretical calculation for the dose of a heterobifunctional compound necessary to achieve a target cell concentration of 230 μ M, with the assumptions below:

- Complete absorption (IV dose or %F = 100);
- Perfect and instantaneous permeability and distribution to every cell in the body;
- No metabolism;

⁴ I certify that Exhibit 1023 is a true and correct copy of Z.X. Wang, "An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule." FEBS Lett 1995 Feb 27;360(2):111-4.


- 3×10^{13} cells in a human⁵;
- $4000 \mu\text{m}^3$ volume of the average mammalian cell⁶;
- Heterobifunctional molecule has a molecular weight (MW) of 800g/M.

19. Using the equation: $(230 \mu\text{M/L}) \times [(1 \times 10^{-6} \text{ M})/\mu\text{M}] \times (800\text{g/M}) \times [(4000 \mu\text{m}^3)/\text{cell}] \times [(1\text{L}/1 \times 10^{15} \mu\text{m}^3)] \times [(3 \times 10^{13} \text{ cells})/\text{human}]$; I obtain a dose of approximately 22 grams. Based on industry experience with the administration of heterobifunctional protein degraders to humans in the clinic, this dose would be highly unusual and suspect with the potential for multiple off-target effects and adverse events.

⁵ See Ex. 1024 at 1 (abstract), 9 (2nd paragraph) (providing estimate of 3×10^{13} cells in a human). I certify that Ex. 1024 is a true and correct copy of Sender et al., Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLOS Biology 14(8): e1002533 (2016).


⁶ See Ex. 1025 at 2 (providing that the volume of an average mammalian tissue culture cell is approximately 4 picoliter). I certify that Ex. 1025 is a true and correct copy of Katherine Luby-Phelps, Cytoarchitecture and Physical Properties of Cytoplasm: Volume, Viscosity, Diffusion, Intracellular Surface Area. International Review of Cytology, Volume 192, 1999, Pages 189-221.

20. I refer to the compound below, which I am told is referred to as Formula AA2, and that A² is the bond to the linker. At C4T, we use heterobifunctional molecules wherein R^{A5} is not hydrogen, for example methyl, as a “null”, or non-active control comparator.



It is our experience that any substituent other than hydrogen at R^{A5}, or a moiety that cleaves to hydrogen *in vivo*, negates the degradation activity of the heterobifunctional molecule by significantly reducing or blocking binding to the E3 ligase cereblon.

21. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief that are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.



Christopher G. Nasveschuk, Ph.D.

10/19/2023

Date

ATTACHMENT 1

Christopher G. Nasveschuk
15 Philips Rd., Stoneham, MA 02180

Experience

C4 Therapeutics, Watertown, Massachusetts
Director of Degron Chemistry
Vice President of Chemical Sciences
Senior Vice President of Chemical Sciences

February 2016 – Present
February 2016 – September 2016
September 2016 – March 2021
March 2021 – Present

Organization and Governance

- Built Chemical Sciences team from the ground up across 5 functional areas. Encompasses medicinal chemistry, process chemistry, DMPK (drug metabolism and pharmacokinetics), CINF (cheminformatics) and CADD (computer-aided drug design) functions.
- Responsible for Chemical Sciences alignment with Discovery and Corporate objectives with respect to resourcing, goals and governance.
- Management of internal and external resourcing and budgeting for the Chemical Sciences team across the discovery and development portfolios as well as strategic partnership portfolios with Calico, Biogen and Roche.
- Responsible for setting the Chemical Sciences Department vision and goals on an annual basis.
- Led the assembly of criteria for project stage gate transitions. The stage gates at C4 are Hit Identification, Lead Identification, Lead Optimization, Development Candidate Short List and Development Candidate Nomination.

Strategic Scientific Contributions

- Led a group of functional area experts to define a budgetary model per phase of the drug discovery process. This model has been used for financial projections and governance decision-making in the context of C4 pipeline and strategic partnership projects.
- Co-developed platform concept at C4T (TORPEDO – Target Oriented Protein Degrader Optimizer) focused on kinetics of targeted protein degradation.
- Co-developed early portfolio strategy – focus on E3 ligase cereblon (CRBN) and pursue both monoDAC (monofunctional degradation-activating compounds or glue degraders) and BiDAC (bifunctional degradation-activating compounds or PROTAC) applications in targeted protein degradation.
- Conceptualized and implemented investigation, investment and intellectual property protection strategy with respect to the E3 ligase CRBN and related chemical matter.
- Co-inventor of >14 New CRBN ligand scaffolds identified, which enabled exploration of new frontiers in the context of degradation kinetics, oral bioavailability, CNS exposure, beyond rule of 5 pharmaceutical properties and business development.
- Led the conception, strategy and scientific platform build for C4's monoDAC (monofunctional degradation-activating compound) platform.
- Inspired and guided Chemical Sciences and project teams to the discovery of 6 development candidates for the C4 Therapeutics portfolio and delivered an additional 5 projects to development candidate short list stage (toxicology data not collected).
- Co-inventor of CFT8634, a BRD9 BiDAC degrader currently in Phase 1 clinical trials.
- Co-inventor of CFT1946, a BRAFV600X BiDAC degrader currently in Phase 1 clinical trials.
- Co-inventor of CFT8919, a EGFR L858R-lineage BiDAC degrader currently in IND enabling studies.

Governance Roles

- Member of Roche JRC, the governing body for the C4T:Roche strategic partnership.
- Member of Calico JRC, the governing body for the C4T:Calico strategic partnership.
- Member of Biogen JSC, the governing body for the C4T:Biogen strategic partnership.
- Member of the AACR Chemistry in Cancer Research Steering Committee. January 2020 – April 2023

Broad Institute, Cambridge, Massachusetts

November 2014 – February 2016

Senior Research Chemist II

November 2014 – February 2016

- Lead chemist on a collaboration project with Calico. Responsible for developing strategic vision, goals, and tactical implementation for targeting a cancer-causing protein with small molecule inhibitors.
- Lead chemist on three additional drug discovery projects. Responsible for project specific goals, mechanism of action studies, and coordinating the teams in order to triage hits to find novel chemical matter for hit to lead medicinal chemistry campaigns.
- Led the CDoT (Center for the Development of Therapeutics) medicinal chemistry team (8 chemists).

Constellation Pharmaceuticals, Cambridge, Massachusetts

May 2009 – November 2014

Research Scientist I

May 2009 – January 2012

Research Scientist II

January 2012 – November 2014

- Part of the lead optimization team that produced CPI-0610, a BET bromodomain inhibitor that is currently being evaluated in Phase 3 clinical trials.
- Co-inventor of CPI-1205, an EZH2 inhibitor currently being evaluated in a phase 2 clinical trials.
- Utilized structure-based design to co-develop the SAR of the isoxazole-azapine class of BET bromodomain inhibitors. Proposed a concept and executed a synthesis of a sub-series of compounds that led to a 3-fold improvement in cellular activity over CPI-0610.
- Helped to build Constellation's EZH2 program from the ground up. Proposed and synthesized a suite of EZH2 cofactor (SAM) mimetics. Evaluation of these compounds led to a method for identification of genuine EZH2 inhibitors through HTS screening.
- Empirically co-developed SAR for the tetramethylpiperidiny1 benzamide class of EZH2 inhibitors progressing a 50 μ M HTS hit to a cell active tool compound for the evaluation of EZH2 biology *in vitro*.
- Successfully merged a new EZH2 "warhead" with SAR from a previous series to generate novel intellectual property, taking a 39 μ M screening hit to a 400 nM cell active lead in three compounds.
- Conceived of the first compound Constellation took *in vivo* to evaluate EZH2i and consequent reduction in the H3K27me3 mark. This compound exhibited a positive PK/PD relationship.
- Through hypothesis-driven modification of the lead EZH2 series, co-developed SAR advancing the series from 5 μ M to 20 nM (cellular potency, <1 nM biochemical potency wt and Y641N mt) in 10 months with good ADME and PK, which enabled oral dosing in efficacy studies.
- Worked with the EZH2 team in batch-mode to rework and rapidly develop a scalable synthesis to a compound of interest, personally delivering 50 grams.
- Proposed core modifications based on existing SAR that led to the filing of two additional patents around Constellation's EZH2 chemical matter.
- Utilized structure-based drug design to co-develop (with Genentech/Constellation collaboration scientists) tool compounds to interrogate the biology of three different bromodomains. Target criteria: fifty-fold selectivity over other bromodomains, <200 nM cellular activity.
- Co-leader of three different collaboration projects with Genentech and Constellation scientists.
- Utilized structure-based drug design to deliver novel concepts that accelerated the delivery of three chemical probe compounds for different bromodomain-containing proteins that enabled the interrogation of chromatin biology.
- Managed 25 external chemists for two years. Aided in transitioning Constellation's external resource to a new CRO (25 chemists). Built relationships and successfully managed the chemistry group through synthetic route and target design which led to a 3-fold increase in productivity.

Education

Post Doctoral Fellow, Advisor: Professor Andrew J. Phillips
University of Colorado-Boulder, Boulder, Colorado

October 2007 - April 2009

- Designed and synthesized histone deacetylase inhibitor (HDACi) depsipeptide natural product Largazole in 8 steps (LLS) and 18% overall yield.
- Synthesized 14 analogs of Largazole probing the structural space about the depsipeptide core leading to compounds with an enhanced profile worthy of intellectual property protection. The patent was subsequently licensed by OnKure Inc. in 2011.
- This work provided the chemistry, pharmacology package and scientific foundation that gave rise to OKI-179, a histone deacetylase inhibitor that is currently in phase 1b/2 clinical trials.

Ph.D. Organic Chemistry, Advisor: Professor Tomislav Rovis
Colorado State University, Fort Collins, Colorado

August 2001 - September 2007

- Developed a suite of Lewis acid-mediated regio- and diastereoselective [1, 3] rearrangements of 1) allylvinyloxyethers (can undergo a competing [3, 3] Claisen rearrangement, 2) 2,5-dihydrooxepins to generate polysubstituted cyclopentenones and 3) 1,3-dioxepins to furnish trisubstituted tetrahydrofurans.
- Applied a diastereoselective [1, 3] rearrangement of a 1,3-dioxepin to synthesize the furofuran lignan Sylvone in 6 steps (LLS) and 36% overall yield.
- Managed the research efforts of 5 undergraduates, guiding the development of their experimental and analytical skills. Co-authored two papers with undergraduate researchers.

B.A. Chemistry, Advisor: Professor Jeffrey H. Byers
Middlebury College, Middlebury, Vermont

September 1997 - May 2001

- Chemistry major: developed a radical atom-transfer addition to pyrrole coupled with an ionic cyclization to produce pyrrolizidine and indolizidine alkaloids.
- Economics minor with a focus on economies in developing countries.
- Captain of the Division I Alpine Ski Team.

U.S. Patents & Published PCT Patent Applications

1. "Selected compounds for targeted degradation of BRD9." Jackson, K. L., Nasveschuk, C. G., Zeid, R., Yin, N., Veits, G. K., Moustakim, M., Yap, J. L., He, M., Yu, R. T., Schnaderbeck, M. J., Neville, K., Jiang, S., Li, M., Liu, Q., Zheng, M., Li, J., Zhang, L. PCT Int. Appln No. WO2023/039208, March 16, 2023.
2. "Compounds for targeting degradation of IRAK4 proteins." Guckian, K. M., Peterson, E. A., Gao, F., Evans, R., Stefan, E., Yap, J. L., Anderson, C. D., O'Shea, M. W., Ahn, J. Y., Nasveschuk, C. G., Henderson, J. A. PCT Int. Appln No. WO2023/283372, January 12, 2023.
3. "Compounds for targeting degradation of IRAK4 proteins." Guckian, K. M., Peterson, E. A., Gao, F., Evans, R., Stefan, E., Yap, J. L., Anderson, C. D., O'Shea, M. W., Ahn, J. Y., Nasveschuk, C. G., Henderson, J. A. PCT Int. Appln No. WO2023/283610, January 12, 2023.
4. "Therapeutics for the degradation of mutant BRAF." Nasveschuk, C. G., Jackson, K. L., Liang, Y., Yu, R. T., Duplessis, M., Fitzgerald, M. E., Garza, V., Good, A. C., O'Shea, M. W., Veits, G. K., Dolente, C., Hewing, D. S., Hunziker, D., Krummenacher, D., Pettazzoni, P. F. T., Wichmann, J. PCT Int. Appln No. WO2022/261250, December 15, 2022.
5. "EGFR degraders to treat cancer metastasis to the brain or CNS." Nasveschuk, C. G., Duplessis, M., Ahn, J. Y., Hird, A. W., Michael, R. E., Lazarski, K., Liang, Y., Aeschke, G., Ricci, A., Goergler, A., Rueher, D. PCT Int. Appln No. WO2022/251539, December 1, 2022.
6. "Tricyclic compounds to degrade neosubstrates for medical therapy." Nasveschuk, C. G., Anderson, C. D., Henderson, J. A., Garza, V., Liang, Y., Moustakim, M., O'Shea, M. W. PCT Int. Appln No.

WO2022/081927, April 21, 2022.

7. *"Tricyclic heterobifunctional compounds for degradation of targeted proteins."* Nasveschuk, C. G., Anderson, C. D., Henderson, J. A., Garza, V., Liang, Y., Moustakim, M., Jackson, K. L., Duplessis, M. PCT Int. Appln No. WO2022/081928, April 21, 2022.
8. *"Tricyclic ligands for degradation of IKZF2 or IKZF4."* Nasveschuk, C. G., Henderson, J. A., Moustakim, M., Good, A. C., Proia, D. PCT Int. Appln No. WO2022/081925, April 21, 2022.
9. *"Compounds for targeted degradation of RET."* Henderson, J. A. Nasveschuk, C. G., Lazarski, K., Garza, V., Moustakim, M., Ahn, J. Y., Veits, G. K., O'Shea, M. W., Michael, R. E., Yap, J. L., Liang, Y., Good, A. C., Fitzgerald, M. E., Yu, R. T. PCT Int. Appln No. WO2022/032026, February 10, 2022.
10. *"BRAF degraders."* Dolente, C., Duplessis, M., Fitzgerald, M. E., Garza, V., Good, A. C., Hewings, D. S., Hunziker, D., Jackson, K. L., Kuhn, B., Liang, Y., Moustakim, M., Nasveschuk, C. G., O'Shea, M. W., Pettazoni, P. F. T., Ricklin, F., Riemer, C., Veits, G. K., Wichmann, J., Yap, J. L., Yu, R. T. PCT Int. Appln No. WO2021/255212, December 23, 2021.
11. *"Compounds for targeted degradation of BRD9."* Nasveschuk, C. G., Zeid, R., Yin, N., Jackson, K. L., Veits, G. K., Moustakim, M., Yap, J. L. PCT Int. Appln No. WO2021/178920, September 10, 2021, and U.S. Patent No. 11,691,972, July 4, 2023.
12. *"Isoindolinone and indazole compounds for the degradation of EGFR."* Nasveschuk, C. G., Duplessis, M., Ahn, J. Y., Hird, A. W., Michael, R. E., Lazarski, K., Liang, Y., Jaeschke, G., Ricci, A., Goergler, A., Rueher, D. PCT Int. Appln No. WO2021/127561, June 24, 2021, and U.S. Patent No. 11,673,902, June 13, 2023.
13. *"Protein tyrosine phosphatase degraders and methods of use thereof."* Veits, G. K., Fitzgerald, M. E., Hird, A. W., Henderson, J. A., Vora, H. U., Sweis, R. F., Kort, M. E., Nasveschuk, C. G., Duplessis, M. PCT Int. Appln No. WO2021/127586; June 24, 2021.
14. *"Heterocyclic compounds for medical treatment."* Nasveschuk, C. G., Norcross, R., Dey, F., Goergler, A., Kuszniir, E. A. PCT Int. Appln No. WO2020/181232, September 10, 2020.
15. *"Targeted protein degradation."* Phillips, A. J., Nasveschuk, C. G., Henderson, J. A., Jackson, K. L., He, M., Liang, Y., Fitzgerald, M. E., Garza, V. PCT Int. Appln No. WO2020/132561, June 25, 2020.
16. *"Compounds for the degradation of BRD9 or MTH1."* Nasveschuk, C. G., Henderson, J. A., Vora, H. U., Veits, G. K., Philips, A. J. PCT Int. Appln No. WO2020/051235, March 12, 2020.
17. *"Spirocyclic compounds."* Dey, F., Goergler, A., Norcross, R., Schmid, P., Nasveschuk, C. G., PCT Int. Appln No. WO2019/236483, December 12, 2019, and U.S. Pat. No. 11,623,929, April 11, 2023.
18. *"Spirocyclic compounds."* Nasveschuk, C. G., Dey, F., Goergler, A., Kuhn, B., Norcross, R., Roevers, S., Schmid, P. PCT Int. Appln No. WO2019/204354, October 24, 2019; U.S. Pat. No. 11,584,748, February 21, 2023.
19. *"Cereblon binders for the degradation of IKAROS."* Veits, G. K., He, M., Henderson, J. A., Nasveschuk, C. G., Phillips, A. J., Good, A. C. PCT Int. Appln No. WO2019/191112, October 3, 2019, and U.S. Patent No. 11,753,397, September 12, 2023.
20. *"Substituted macrocyclic indole derivatives."* Thede, K., Mengel, A., Christ, C., Kuhnke, J., Johannes, S. A. L., Buchgraber, P., Klar, U., Sack, U., Kaulfuss, S., Fernandez-Montalvan, A. E., Werbeck, N., Mönning, U., Nowak-Reppel, K., Wittrock, S., McKinney, D., Serrano-Wu, M., H., Lemke, C., Fitzgerald, M., Nasveschuk, C., Lazarski, K., Ferrara, S. J., Furst, L., Wei, G., McCarren, P. R., Harvey, R. A., PCT Int. Appln. No. WO2019/096922, May 23, 2019; U.S. Pat. No. 11,440,923, September 13, 2022.
21. *"Degraders and degrons for targeted protein degradation."* Phillips, A. J., Nasveschuk, C. G., Henderson, J. A., He, M., Lazarski, K. PCT Int. Appln No. WO2019/099868, May 23, 2019; U.S. Pat. No. 11,524,949, December 13, 2022.
22. *"Macrocyclic chlorine substituted indole derivatives."* Thede, K., Mengel, A., Christ, C., Kuhnke, J., Johannes, S. A. L., Buchgraber, P., Klar, U., Sack, U., Kaulfuss, S., Fernandez-Montalvan, A. E., Werbeck, N., Mönning, U., Nowak-Reppel, K., Lemke, C., Serrano-Wu, M. H., McKinney, D., Fitzgerald, M., Nasveschuk, C., Lazarski, K., Ferrara, S. J., Furst, L., Wei, G., McCarren, P. R., Harvey, R. A., Payne, D., Pesnot, T., Wilson, C. PCT Int. Appln No. WO2019/096905; May 23, 2019; U.S. Pat. No. 11,478,451,

October 25, 2022.

23. *"Macrocyclic indole derivatives."* Furst, L., Serrano-Wu, M. H., Lemke, C., McKinney, D., Fitzgerald, M., Nasveschuk, C., Lazarski, K., Ferrara, S. J., Wei, G., McCarren, P. R., Thede, K., Mengel, A., Christ, C., Kuhnke, J., Johannes, S. A. L., Buchgraber, P., Klar, U., Sack, U., Kaulfuss, S., Fernandez-Montalvan, A. E., Werbeck, N., Mönning, U., Nowak-Reppel, K. PCT Int. Appln No. WO2019/096911, May 23, 2019; U.S. Pat. No. 11,401,278, August 2, 2022.
24. *"Macrocyclic chlorine substituted indole derivatives."* Thede, K., Mengel, A., Christ, C., Kuhnke, J., Johannes, S. A. L., Buchgraber, P., Klar, U., Sack, U., Kaulfuss, S., Fernandez-Montalvan, A. E., Werbeck, N., Mönning, U., Nowak-Reppel, K., Mortier, J. X., McCarren, P. R., Serrano-Wu, M. H., Lemke, C., McKinney, D., Fitzgerald, M., Nasveschuk, C., Lazarski, K., Ferrara, S. J., Furst, L., Wei, G., Harvey, R. A., Payne, D., Pesnot, T., Wilson, C. PCT Int. Appln. No. WO2019/096914, May 23, 2019; U.S. Pat. No. 11,447,504, September 20, 2022.
25. *"Macrocyclic fluorine substituted indole derivatives as MCL-1 inhibitors, for use in the treatment of cancer."* Ferrara, S. J., Serrano-Wu, M. H., Lemke, C., McKinney, D., Fitzgerald, M., Nasveschuk, C., Lazarski, K., Furst, L., Wei, G., McCarren, P. R., Thede, K., Mengel, A., Christ, C., Kuhnke, J., Johannes, S. A. L., Buchgraber, P., Klar, U., Sack, U., Kaulfuss, S., Fernandez-Montalvan, A. E., Werbeck, N., Mönning, U. PCT Int. Appln. No. WO2019/096909, May 23, 2019; U.S. Pat. No. 11,286,263, March 29, 2022.
26. *"Aryl annulated macrocyclic indole derivatives."* Thede, K., Mengel, A., Christ, C., Kuhnke, J., Johannes, S. A. L., Buchgraber, P., Klar, U., Sack, U., Kaulfuss, S., Fernandez-Montalvan, A. E., Werbeck, N., Mönning, U., Ferrara, S. J., Serrano-Wu, M. H., Lemke, C., McKinney, D., Fitzgerald, M., Nasveschuk, C., Lazarski, K., Furst, L., Wei, G., McCarren, P. R., Harvey, R. A., Wilson, C. PCT Int. Appln. No. WO2019/096907, May 23, 2019.
27. *"N/O-linked degrons and degronimers for protein degradation."* Phillips, A. J., Nasveschuk, C. G., Henderson, J. A., Liang, Y., He, M., Duplessis, M., Chen, C. PCT Int. Appln. No. WO2018/237026, December 27, 2018; and U.S. Patent No. 11,459,335, October 4, 2022.
28. *"Macrocyclic indole derivatives."* Wagner, S.; Buchgraber, P.; Klar, U.; Christ, C.; Fernandez-Montalvan, A. E.; Mowes, M.; Lienau, P.; Eis, K.; Sack, U.; Monning, U.; Scholz, A.; Kuhnke, J.; Thede, K.; Webeck, N.; Serrano-Wu, M.; Lemke, C.; McKinney, D.; Fitzgerald, M.; Nasveschuk, C.; Lazarski, K.; Ferrara, S.J.; Furst, L.; Wei, G.; McCarren, P. R. PCT Int. Appl. No. WO2017/198341, November 23, 2017; U.S. Patent No. 10,981,932, April 20, 2021; and U.S. Pat. No. 11,492,358, November 8, 2022.
29. *"Spirocyclic degronimers for target protein degradation."* Phillips, A. J.; Nasveschuk, C. G.; Henderson, J. A.; Liang, Y.; Lazarski, K.; Michael, R. E. PCT Int. Appl. No. WO2017/197036, November 16, 2017; U.S. Pat. No. 10,660,968, May 26, 2020; and U.S. Pat. No. 11,185,592, November 30, 2021.
30. *"Heterocyclic degronimers for target protein degradation."* Phillips, A. J.; Nasveschuk, C. G.; Henderson, J. A.; Liang, Y.; Fitzgerald, M.E.; He, M.; Michael, R. E. PCT Int. Appl. No. WO2017/197055, November 16, 2017; U.S. Pat. No. 10,646,575, May 12, 2020; and U.S. Pat. No. 10,905,768, February 2, 2021.
31. *"Amine-linked C3-glutarimide degronimers for target protein degradation."* Phillips, A. J.; Nasveschuk, C. G.; Henderson, J. A.; Liang, Y.; Chen, C.-L.; Duplessis, M.; He, M.; Lazarski, K. PCT Int. Appl. No. WO2017/197051, November 16, 2017.
32. *"C3-Carbon linked glutarimide degronimers for target protein degradation."* Phillips, A. J.; Nasveschuk, C. G.; Henderson, J. A.; Liang, Y.; He, M.; Lazarski, K.; Veits, G. K.; Vora, H. U. PCT Int. Appl. No. WO2017/197046, November 16, 2017; and U.S. Pat. No. 10,849,982, December 1, 2022.
33. *"Bromodomain targeting degronimers for target protein degradation."* Phillips, A. J.; Nasveschuk, C. G.; Henderson, J. A.; Liang, Y.; Fitzgerald, M. E.; Michael, R. E. PCT Int. Appl. No. WO2017/197056, November 16, 2017.
34. *"Therapeutic pyridazine compounds and uses thereof."* Albrecht, B. K.; Cote, A.; Crawford, T.; Duplessis, M.; Good, A.C.; Leblanc, Y.; Magnuson, S.R.; Nasveschuk, C. G.; Romero, F. A.; Tang, Y.; Taylor, A. M. PCT Int. Appl. No. WO2016/138114, September 1, 2016; and U.S. Pat. No. 10,308,614, June 4, 2019.
35. *"Therapeutic compounds and uses thereof."* Alder, M.; Burdick, D. J.; Crawford, T.; Duplessis, M.; Magnuson, S.; Nasveschuk, C. G.; Romero, F. A.; Tang, Y.; Tsui, V. H.-W.; Wang, S. PCT Int. Appl. No.

WO2016/123391, August 4, 2016; and U.S. Pat. No. 10,202,378, February 12, 2019.

36. *"Therapeutic compounds and uses thereof."* Albrecht, B. K.; Audia, J. E.; Cote, A.; Duplessis, M.; Gehling, V.; Good, A. C.; Harmange, J.-C.; Leblanc, Y.; Nasveschuk, C. G.; Taylor, A. M.; Vaswani, R. G. PCT Int. Appl. No. WO2016/123387, August 4, 2016; and U.S. Pat. No. 10,301,253, May 28, 2019.
37. *"(Piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase KDM2b for the treatment of cancer."* Albrecht, B. K.; Cote, A.; Gehling, V.; Hsiao-Wei Tsui, V.; Kiefer Jr., J. R.; Liang, J.; Magnuson, S.; Nasveschuk, C. G.; Pastor, R.; Romero, F. A.; Taylor, A. M.; Zhang, B. PCT Int. Appl. No. WO2016/112284, July 14, 2016; and U.S. Pat. No. 10,280,149, May 7, 2019.
38. *"4,5-Dihydroimidazole derivatives and their use as histone demethylase (KDM2b) inhibitors."* Albrecht, B. K.; Cote, A.; Gehling, V.; Hsiao-Wei Tsui, V.; Kiefer Jr., J. R.; Liang, J.; Magnuson, S.; Nasveschuk, C. G.; Romero, F. A.; Taylor, A. M. PCT Int. Appl. No. WO2016/112251, July 14, 2016; and U.S. Pat. No. 10,202,354, February 12, 2019.
39. *"Pyridazinone derivatives and their use in the treatment of cancer."* Albrecht, B. K.; Burdick, D. J.; Cote, A.; Duplessis, M.; Nasveschuk, C. G.; Taylor, A. M. PCT Int. Appl. No. WO2016/112298, July 14, 2016; and U.S. Pat. No. 10,239,861, March 26, 2019.
40. *"Substituted pyrrolopyridines as inhibitors of bromodomain."* Albrecht, B. K.; Bellon, S. F.; Burdick, D. J.; Cote, A.; Crawford, T.; Dakin, L. A.; Hewitt, M. C.; Hsiao-Wei Tsui, V.; Leblanc, Y.; Magnuson, S. R.; Nasveschuk, C. G.; Romero, F. A.; Tang, Y.; Taylor, A. M.; Wang, S. PCT Int. Appl. No. WO2016/077378, May 19, 2016; and U.S. Pat. No. 10,183,009, January 22, 2019.
41. *"Substituted pyrrolopyridines as inhibitors of bromodomain."* Albrecht, B. K.; Bellon, S. F.; Burdick, D. J.; Cote, A.; Crawford, T.; Dakin, L. A.; Hewitt, M. C.; Hsiao-Wei Tsui, V.; Leblanc, Y.; Magnuson, S. R.; Nasveschuk, C. G.; Romero, F. A.; Tang, Y.; Taylor, A. M.; Wang, S. PCT Int. Appl. No. WO2016/077380, May 19, 2016; and U.S. Pat. No. 10,150,767, December 11, 2018.
42. *"Bromodomain inhibitors and uses thereof."* Albrecht, B. K.; Bellon, S. F.; Burdick, D. J.; Cote, A.; Crawford, T.; Dakin, L. A.; Hsiao-Wei Tsui, V.; Hewitt, M. C.; Leblanc, Y.; Magnuson, S. R.; Nasveschuk, C. G.; Romero, F. A.; Tang, Y.; Taylor, A. M.; Wang, S. PCT Int. Appl. No. WO2016/077375, May 19, 2016; and U.S. Pat. No. 10,258,603, April 16, 2019.
43. *"Therapeutic compounds and uses thereof."* Romero, F. A.; Magnuson, S.; Pastor, R.; Tsui, V. H.-W.; Murray, J.; Crawford, T.; Burdick, D. J.; Albrecht, B. K.; Cote, A.; Taylor, A. M.; Nasveschuk, C. G.; Leblanc, Y.; Hewitt, M. C.; Lai, K. W.; Chen, K. PCT Int. Appl. No. WO2016/055028, April 14, 2016; and U.S. Pat. No. 10,206,931, February 19, 2019.
44. *"Therapeutic compounds and uses thereof."* Albrecht, B. K.; Cote, A.; Crawford, T.; Duplessis, M.; Good, A.C.; Leblanc, Y.; Magnuson, S.; Nasveschuk, C. G.; Pastor, R.; Romero, F. A.; Taylor, A. M. PCT Int. Appl. No. WO2016/036873, March 10, 2016; and U.S. Pat. No. 10,358,437, July 23, 2019.
45. *"Phthalazine derivatives of formula (I) as PCAF and GCN5 inhibitors for use in the treatment of cancer."* Albrecht, B. K.; Cote, A.; Crawford, T.; Duplessis, M.; Good, A.C.; Leblanc, Y.; Magnuson, S.; Nasveschuk, C. G.; Pastor, R.; Romero, F. A.; Taylor, A.M. PCT Int. Appl. No. WO2016/036954, March 10, 2016; and U.S. Pat. No. 10,155,764, December 18, 2018.
46. *"Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof."* Albrecht, B. K.; Audia, J. E.; Dakin, L. A.; Duplessis, M.; Gehling, V. S.; Harmange, J.-C.; Nasveschuk, C. G.; Vaswani, R. G. PCT Int. Appl. No. WO2015/023915, February 19, 2015; and U.S. Pat. No. 9,969,716, May 15, 2018.
47. *"Modulators of methyl modifying enzymes, compositions and uses thereof."* Albrecht, B. K.; Audia, J. E.; Cook, A.; Cote, A.; Dakin, L. A.; Gehling, V. S.; Harmange, J.-C.; Nasveschuk, C. G.; Vaswani, R. PCT Int. Appl. No. WO2014/151142, September 25, 2014; and U.S. Pat. No. 9,745,305, August 29, 2017.
48. *"Treating TH2-mediated diseases by inhibition of bromodomain-comprising proteins BRD7 and BRD9."* Albrecht, B. K.; Cote, A.; Crawford, T.; Fauber, B.; Huang, H.-R.; Lora, J. M.; Magnuson, S.; Nasveschuk, C. G.; Salmeron, A.; Sims II, R. J.; Taylor, A. M. PCT Int. Appl. No. WO2014/144721, September 18, 2014.

49. "Modulators of methyl modifying enzymes, compositions and uses thereof." Albrecht, B. K.; Audia, J. E.; Cook, A. S.; Dakin, L. A.; Duplessis, M.; Gehling, V. S.; Harmange, J.-C.; Nasveschuk, C. G.; Vaswani, R. G. PCT Int. Appl. No. WO2014/124418, August 14, 2014; U.S. Pat. No. 9,469,646, October 18, 2016, now Reissued Pat. No. RE47,428E, June 11, 2019; and 10,016,405, July 10, 2018.
50. "Modulators of methyl modifying enzymes, compositions and uses thereof." Albrecht, B. K.; Audia, J. E.; Cook, A. S.; Dakin, L. A.; Duplessis, M.; Gehling, V. S.; Harmange, J.-C.; Nasveschuk, C. G.; Vaswani, R. PCT Int. Appl. No. WO2013/120104, August 15, 2013; U.S. Pat. No. 9,085,583, July 21, 2015; U.S. Pat. No. 9,371,331, June 21, 2016; and U.S. Pat. No. 9,980,952, May 29, 2018.
51. "Modulators of methyl modifying enzymes, compositions and uses thereof." Albrecht, B. K.; Audia, J. E.; Cook, A. S.; Gagnon, A.; Harmange, J.-C.; Nasveschuk, C. G. PCT Int. Appl. No. WO2013/075083, May 23, 2013; U.S. Pat. No. 9,206,128, December 8, 2015.
52. "Modulators of methyl modifying enzymes, compositions and uses thereof." Albrecht, B. K.; Audia, J. E.; Gagnon, A.; Harmange, J.-C.; Nasveschuk, C. G. PCT Int. Appl. No. WO2013/075084, May 23, 2013; U.S. Pat. No. 9,051,269, June 9, 2015; and U.S. Pat. No. 9,409,865, August 9, 2016.
53. "Bromodomain inhibitors and uses thereof." Albrecht, B. K.; Audia, J. E.; Côté, A.; Gehling, V. S.; Harmange, J.-C.; Hewitt, M. C.; Leblanc, Y.; Nasveschuk, C. G.; Taylor, A. M.; Vaswani, R. G. PCT. Int. Appl. No. WO2012/075383, June 7, 2012; U.S. Pat. No. 8,796,261, August 5, 2014; and U.S. Pat. No. 9,522,920, December 20, 2016.
54. "Bromodomain inhibitors and uses thereof." Albrecht, B. K.; Audia, J. E.; Côté, A.; Gehling, V. S.; Harmange, J.-C.; Hewitt, M. C.; Nasveschuk, C. G.; Taylor, A. M.; Vaswani, R. G. PCT. Int. Appl. WO2012/075456, June 7, 2012; U.S. Pat. No. 9,249,161, February 2, 2016.
55. "Modulators of methyl modifying enzymes, compositions and uses thereof." Albrecht, B. K.; Audia, J. E.; Harmange, J. C.; Nasveschuk, C. G. PCT. Int. Appl. No. WO2013/078320, May 30, 2013.
56. "Modulators of methyl modifying enzymes, compositions and uses thereof." Albrecht, B. K.; Audia, J. E.; Gagnon, A.; Harmange, J.-C.; Nasveschuk, C. G. PCT. Int. Appl. No WO2012/068589, May 24, 2012.
57. "Macrocyclic compounds useful as inhibitors of histone deacetylases." Liu, X.; Phillips, A. J.; Ungermannova, D.; Nasveschuk, C. G.; Zhang, G. PCT. Int. Appl. No. WO2011/150283, December 1, 2011.

Publications

1. "GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1." Taylor, A. M.; Bailey, C.; Belmont, L. D.; Campbell, R.; Cantone, N.; Cote, A.; Crawford, T. D.; Cummings, R.; DeMent, K.; Duplessis, M.; Flynn, M.; Good, A. C.; Huang, H.-R.; Joshi, S.; Leblanc, Y.; Murray, J.; Nasveschuk, C. G.; et. al. *J. Med. Chem.* **2022**, 65(16), 11177-11186.
2. "Preclinical development of the class-I-selective histone deacetylase inhibitor OKI-179 for the treatment of solid tumors." Diamond, J. R.; Pitts, T. M.; Ungermannova, D.; Nasveschuk, C. G.; et. al. *Mol. Can. Ther.* **2022**, 21(3), 397-406.
3. "Structural Characterization of Degradable-Induced Ternary Complexes Using Hydrogen-Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design." Eron, S. J.; Huang, H.; Agafonov, R. V.; Fitzgerald, M. E.; Patel, J.; Michael, R. E.; Lee, T. D.; Hart, A.; Shaulsky, J.; Nasveschuk, C. G.; et. al. *ACS Chem. Bio.* **2021**, 16(11), 2228-2243.
4. "Evaluation of the small-molecule BRD4 degrader CFT-2718 in small-cell lung cancer and pancreatic cancer models." Danlin, S.; Nikonova, A. S.; Zhang, P.; Deneka, A. Y.; Fitzgerald, M. E.; Michael, R. E.; Lee, L.; Lilly, A. C.; Fisher, S. L.; Phillips, A. J.; Nasveschuk, C. G.; et. al. *Mol. Can. Ther.* **2021**, 20(8), 1367-1377.
5. "A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination." Vieux, E. F.; Agafonov, R. V.; Emerson, L.; Isasa, M.; Diebler, R. W.; Simard, J. R.; Cocozziello, D.; Ladd, B.; Lee, L.; Li, H.; Archer, S.; Fitzgerald, M.; Michael, R.; Nasveschuk, C. G.; et. al. *SLAS Discovery*, **2021**, 26(4), 547-559.
6. "Development of an AchillesTAG degradation system and its application to control CAR-T activity." Veits,

- G. K.; Henderson, C. S.; Vogelaar, A.; Eron, S. J.; Lee, L.; Hart, A.; Deibler, R. W.; Baddour, J.; Elam, W. A.; Agafonov, R. V.; Freda, J.; Chaturvedi, P.; Ladd, B.; Carlson, M. W.; Vora, H. U.; Scott, T. G.; Tieu, T.; Jain, A.; Chen, C.-L.; Kibbler, E. S.; Pop, M. S.; He, M.; Kern, G.; Maple, H. J.; Marsh, G. P.; Norley, M. C.; Oakes, C. S.; Henderson, J. A.; Sowa, M. E.; Phillips, A. J.; Proia, D. A.; Park, E. S.; Patel, J. S.; Fisher, S. L.; Nasveschuk, C. G.; Zeid, R. *Curr. Res. Chem. Bio.* **2021**, 1, 100010.
7. "GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like." Wang, S.; Tsui, V.; Crawford, T. D.; Audia, J. E.; Burdick, D. J.; Beresini, M. H.; Cote, A.; Cummings, R.; Duplessis, M.; Flynn, E. M.; Hewitt, M. C.; Huang, H.-R.; Jayaram, H.; Jiang, Y.; Joshi, S.; Murray, J.; Nasveschuk, C. G.; Pardo, E.; Poy, F.; Romero, F. A.; Tang, Y.; Taylor, A. M.; Wang, J.; Xu, Z.; Zawadzke, L. E.; Zhu, X.; Albrecht, B. K.; Magnuson, S. R.; Bellon, S.; Cochran, A. G. *J. Med. Chem.* **2018**, 61(20), 9301-9315.
 8. "GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)." Crawford, T. D.; Audia, J. E.; Bellon, S.; Burdick, D. J.; Bommi-Reddy, A.; Côté, A.; Cummings, R. T.; Duplessis, M.; Flynn, E. M.; Hewitt, M.; Huang, H.-R.; Jayaram, H.; Jiang, Y.; Joshi, S.; Kiefer, J. R.; Murray, J.; Nasveschuk, C. G.; Neiss, A.; Pardo, E.; Romero, F. A.; Sandy, P.; Sims, R. J 3rd; Tang, Y.; Taylor, A. M.; Tsui, V.; Wang, J.; Wang, S.; Wang, Y.; Xu, Z.; Zawadzke, L.; Zhu, X.; Albrecht, B. K.; Magnuson, S. R.; Cochran, A. G. *ACS Med. Chem. Lett.* **2017**, 8(7), 737-741.
 9. "Inhibition of Bromodomain-Containing Protein 9 for the Prevention of Epigenetically-Defined Drug Resistance." Crawford, T. D.; Vartanian, S.; Côté, A.; Bellon, S.; Duplessis, M.; Flynn, E. M.; Hewitt, M.; Huang, H.-R.; Kiefer, J. R.; Murray, J.; Nasveschuk, C. G.; Pardo, E.; Romero, F. A.; Sandy, P.; Tang, Y.; Taylor, A. M.; Tsui, V.; Wang, J.; Wang, S.; Zawadzke, L.; Albrecht, B. K.; Magnuson, S. R.; Cochran, A. G.; Stokoe, D. *Bioorg. Med. Chem. Lett.* **2017**, 27(15), 3534-3541.
 10. "Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas." Vaswani, R. G.; Gehling, V. S.; Dakin, L. A.; Cook, A. S.; Nasveschuk, C. G.; Duplessis, M.; Iyer, P.; Balasubramanian, S.; Zhao, F.; Good, A. C.; Campbell, R.; Lee, C.; Cantone, N.; Cummings, R. T.; Normant, E.; Bellon, S. F.; Albrecht, B. K.; Harmange, J.-C.; Trojer, P.; Audia, J. E.; Zhang, Y.; Justin, N.; Chen, S.; Wilson, J. R.; Gamblin, S. J. *J. Med. Chem.* **2016**, 59(21), 9928-9941.
 11. "Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(1), BRD9, and CECR2 Bromodomains." Crawford, T. D.; Tsui, V.; Flynn, E. M.; Wang, S.; Taylor, A. M.; Côté, A.; Audia, J. E.; Beresini, M. H.; Burdick, D. J.; Cummings, R.; Dakin, L. A.; Duplessis, M.; Good, A. C.; Hewitt, M. C.; Huang, H.-R.; Jayaram, H.; Kiefer, J. R.; Jiang, Y.; Murray, J.; Nasveschuk, C. G.; Pardo, E.; Poy, F.; Romero, F. A.; Tang, Y.; Wang, J.; Xu, Z.; Zawadzke, L. E.; Zhu, X.; Albrecht, B. K.; Magnuson, S. R.; Bellon, S.; Cochran, A. G. *J. Med. Chem.* **2016**, 59(11), 5391-5402.
 12. "Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)." Taylor, A. M.; Côté, A.; Hewitt, M. C.; Pastor, R.; Leblanc, Y.; Nasveschuk, C. G.; Romero, F. A.; Crawford, T. D.; Cantone, N.; Jayaram, H.; Setser, J.; Murray, J.; Beresini, M. H.; de Leon B. G.; Chen, Z.; Conery, A. R.; Cummings, R. T.; Dakin, L. A.; Flynn, E. M.; Huang, O. W.; Kaufman, S.; Keller, P. J.; Kiefer, J. R.; Lai, T.; Li, Y.; Liao, J.; Liu, W.; Lu, H.; Pardo, E.; Tsui, V.; Wang, J.; Wang, Y.; Xu, Z.; Yan, F.; Yu, D.; Zawadzke, L.; Zhu, X.; Zhu, X.; Sims, R. J 3rd; Cochran, A. G.; Bellon, S.; Audia, J. E.; Magnuson, S.; Albrecht, B. K. *ACS Med. Chem. Lett.* **2016**, 7(5), 531-536.
 13. "Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains." Taylor, A. M.; Vaswani, R. G.; Gehling, V. S.; Hewitt, M. C.; Leblanc, Y.; Audia, J. E.; Bellon, S.; Cummings, R. T.; Côté, A.; Harmange, J.-C.; Jayaram, H.; Joshi, S.; Lora, J. M.; Mertz, J. A.; Neiss, A.; Pardo, E.; Nasveschuk, C. G.; Poy, F.; Sandy, P.; Setser, J. W.; Sims, R. J 3rd; Tang, Y.; Albrecht, B. K. *ACS Med. Chem. Lett.* **2016**, 7(2), 145-150.
 14. "Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials." Albrecht, B. K.; Gehling, V. S.; Hewitt, M. C.

- Vaswani, R. G; Côté, A.; Leblanc, Y.; Nasveschuk, C. G; Bellon, S.; Bergeron, L.; Campbell, R.; Cantone, N.; Cooper, M. R; Cummings, R. T; Jayaram, H.; Joshi, S.; Mertz, J. A; Neiss, A.; Normant, E.; O'Meara, M.; Pardo, E.; Poy, F.; Sandy, P.; Supko, J.; Sims, R. J 3rd; Harmange, J.-C.; Taylor, A. M; Audia, J. E. *J. Med. Chem.* **2016**, 59(4), 1330-1339.
15. "Discovery, Design, and Synthesis of Indole-Based EZH2 Inhibitors." Gehling, V. S; Vaswani, R. G; Nasveschuk, C. G; Duplessis, M.; Iyer, P.; Balasubramanian, S.; Zhao, F.; Good, A. C; Campbell, R.; Lee, C.; Dakin, L. A; Cook, A. S; Gagnon, A.; Harmange, J.-C.; Audia, J. E; Cummings, R. T; Normant, E.; Trojer, P.; Albrecht, B. K. *Bioorg. Med. Chem. Lett.* **2015**, (25)17, 3644-3649.
 16. "Development of Methyl Isoxazoleazepines as Inhibitors of BET." Hewitt, M. C; Leblanc, Y.; Gehling, V. S; Vaswani, R. G; Côté, A.; Nasveschuk, C. G; Taylor, A. M; Harmange, J.-C.; Audia, J. E; Pardo, E.; Cummings, R.; Joshi, S.; Sandy, P.; Mertz, J. A; Sims, R. J 3rd; Bergeron, L.; Bryant, B. M; Bellon, S.; Poy, F.; Jayaram, H.; Tang, Y.; Albrecht, B. K. *Bioorg. Med. Chem. Lett.* **2015**, 25(9), 1842-1848.
 17. "EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation." Bradley, W. D.; Arora, S.; Busby, J.; Balasubramanian, S.; Gehling, V. S.; Nasveschuk, C. G.; Vaswani, R. G.; Yuan, C.-C.; Hatton, C.; Zhao, F.; Williamson, K. E.; Iyer, P.; Mendez, J.; Campbell, R.; Cantone, N.; Garapaty-Rao, S.; Audia, J. E.; Cook, A. S.; Dakin, L. A.; Albrecht, B. K.; Harmange, J.-C.; Daniels, D. L.; Cummings, R. T.; Bryant, B. M.; Normant, E.; Trojer, P. *Chem. Biol.* **2014**, 21(11), 1463-1475.
 18. "A Practical Synthesis of Indoles via a Pd-Catalyzed C-N Ring Formation." Vaswani, Rishi G.; Albrecht, Brian K.; Audia, James E.; Cote, Alexandre; Dakin, Les A.; Duplessis, Martin; Gehling, Victor S.; Harmange, Jean-Christophe; Hewitt, Michael C.; Leblanc, Yves; Nasveschuk, Christopher G.; Taylor, Alexander M. *Org. Lett.* **2014**, 16, 4144-4117.
 19. "Discovery and Optimization of TetramethylpiperidinyI Benzamides as Inhibitors of EZH2." Nasveschuk, C. G.; Gagnon, A.; Garapaty-Rao, S.; Balasubramanian, S.; Campbell, R.; Lee, C.; Zhao, F.; Bergeron, L.; Cummings, R.; Trojer, P.; Audia, J. E.; Albrecht, B. K.; Harmange, J.-C. *ACS Med. Chem. Lett.* **2014**, 5, 378-383.
 20. "Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth." Garapaty-Rao, S.; Nasveschuk, C. G.; Gagnon, A.; Chan, E. Y.; Sandy, P.; Busby, J.; Balasubramanian, S.; Campbell, R.; Zhao, F.; Bergeron, L.; Audia, J. E.; Albrecht, B. K.; Harmange, J.-C.; Trojer, P. *Chem. Biol.* **2013**, 20, 1329-1339.
 21. "Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors." Gehling, V. S.; Hewitt, M. C.; Vaswani, R. G.; Leblanc, Y.; Côté, A.; Nasveschuk, C. G.; Taylor, A. M.; Harmange, J.-C.; Audia, J. E.; Pardo, E.; Joshi, S.; Sandy, P.; Mertz, J. A.; Sims III, R. J.; Bergeron, L.; Bryant, B.; Bellon, S.; Poy, F.; Jayaram, H.; Sankaranarayanan, R.; Yellapantula, S.; Srinivasamurthy, N. B.; Birudukota, S.; Albrecht, B. K. *ACS Med. Chem. Lett.* **2013**, 4, 835-840.
 22. "Largazole and Its Derivatives Selectively Inhibit Ubiquitin Activating Enzyme (E1)." Ungermannova, D.; Parker, S. J.; Nasveschuk, C. G.; Chapnick, D. A.; Phillips, J. A.; Kuchta, R. D.; Liu, X. *PLoS One*, **2012**, 7, e29208.
 23. "Identification and Mechanistic Studies of a Novel Ubiquitin E1 Inhibitor." Ungermannova, D.; Parker, S. J.; Nasveschuk, C. G.; Chapnick, D. A.; Phillips, A. J.; Kuchta, R. D.; Liu, X. *J. Biomol. Screen.* **2012**, 17, 421-434.
 24. "A Concise Total Synthesis of Largazole, Solution Structure, and Some Preliminary Structure Activity Relationships." Nasveschuk, C. G.; Ungermannova, D.; Liu, X.; Phillips, A. J. *Org. Lett.* **2008**, 10, 3595-3598.
 25. "A Diastereoselective Ring Contraction of 1,3-Dioxepins to 2,3,4-Trisubstituted and Tetrasubstituted Tetrahydrofurans." Nasveschuk, C. G.; Rovis, T. *J. Org. Chem.* **2008**, 73, 612-617.
 26. "A Rapid Total Synthesis of (±)-Sylvone." Nasveschuk, C. G.; Rovis, T. *Synlett* **2008**, 1, 126-128.
 27. "Review The [1, 3] O-to-C rearrangement: opportunities for stereoselective synthesis." Nasveschuk, C. G.; Rovis, T. *Org. Biomol. Chem.* **2007**, 6, 240-254.
 28. "A Diastereoselective Intermolecular Heck Reaction of 1,3-Dioxepins." Nasveschuk, C. G.; Frein, J. D.;

- Jui, N. T.; Rovis, T. *Org. Lett.* **2007**, 9, 5099-5102.
29. "A modular approach to the synthesis of 2,3,4-trisubstituted tetrahydrofurans." Nasveschuk, C. G.; Jui, N. T.; Rovis, T. *Chem. Commun.* **2006**, 3119-3121.
30. "Regioselective Lewis Acid-Mediated [1,3] Rearrangement of Allylvinyl Ethers." Nasveschuk, C. G.; Rovis, T. *Org. Lett.* **2005**, 7, 2173-2176.
31. "Stereoselective Lewis Acid Mediated [1,3] Ring Contraction of 2,5-Dihydrooxepins as a Route to Polysubstituted Cyclopentenones." Nasveschuk, C. G.; Rovis, T. *Angew. Chem. Int. Ed.* **2005**, 44, 3264-3267.
32. "Tandem radical-electrophilic annulations to pyrrole." Byers, J. H.; DeWitt, A.; Nasveschuk, C. G.; Swigor, J. E. *Tet. Lett.* **2004**, 45, 6587-6590.

Presentations and Posters

1. "Molecular Glue Degraders: Access to New Mechanisms and Disease Targets." Invited Seminar, Educational Session at 2023 AACR National Meeting, Orlando, FL, April 2023.
2. "Monofunctional Degradation Activating Compounds: From New Targets to the Clinic." Invited Seminar, TPD Summit, Danvers, MA, October 2022.
3. "The Discovery and Characterization of CFT8634: A Potent and Selective Degradator of BRD9 for the Treatment of SMARCB1-Perturbed Cancers." Poster Presentation, Medicinal Chemistry GRC, New London, NH, August 2022.
4. "Targeted Protein Degradation: Access to New Medicines by Drugging Challenging Targets." Invited Seminar, Educational Session at 2022 AACR National Meeting, New Orleans, LA, April 2022.
5. "Development of an AchillesTAG Degradation System and its Application to Control CAR-T Activity." Invited Seminar, Broad Institute Virtual Seminar, September 2021.
6. "BRD9 Degradation: Selectivity considerations en route to the discovery of an in vivo tool compound with activity in a Synovial Sarcoma model." Poster Presentation, Medicinal Chemistry GRC, New London, NH, August 2021.
7. "Degradator Drug Space: What Rules?" Invited Seminar, Ubiquitin-Induced Targeted Protein Degradation Conference Virtual Session, August 2021.
8. "MTH1 Achilles Tag: Target-Centric Design of Heterobifunctional Degradators." Invited Seminar, St. Jude Children's Research Hospital, Memphis, TN, February 2020.
9. "MTH1 Achilles Tag: Target-Centric Design of Heterobifunctional Degradators." Invited Seminar, Targeted Protein Degradation Summit, Boston, MA, October 2019.
10. "Degradator Drug Space: What Rules?" Invited Seminar, HT-ADME Conference, Cambridge, MA, June 2019.
11. "Advances in the Medicinal Chemistry of Targeted Protein Degradation." Invited Seminar, Wesleyan University, Middletown, CT, November 2018.
12. "The PROTAC Drug Approach." Invited Seminar, SNO Annual Meeting, New Orleans, LA, November 2018.
13. "Advances in the Medicinal Chemistry of Targeted Protein Degradation." Invited Seminar, Medicinal Chemistry GRC, New London, NH, August 2018.
14. "EZH2i: in vitro Activity to in vivo Efficacy." Poster, GRC Heterocyclic Chemistry, Salve-Regina University, Newport, RI, June 2014.
15. "Discovery and Application of EZH2 Inhibitors." Poster, GRC Heterocyclic Chemistry, Salve-Regina University, Newport, RI, June 2013.
16. "Identification, Characterization and Optimization of a Class of Inhibitors of the Catalytic Activity of the PRC2 Complex." Invited Seminar, UQAM, Montréal, QC, November 2012.